[go: up one dir, main page]

CA2195779A1 - Composition et methode de protection contre la toxicomanie - Google Patents

Composition et methode de protection contre la toxicomanie

Info

Publication number
CA2195779A1
CA2195779A1 CA002195779A CA2195779A CA2195779A1 CA 2195779 A1 CA2195779 A1 CA 2195779A1 CA 002195779 A CA002195779 A CA 002195779A CA 2195779 A CA2195779 A CA 2195779A CA 2195779 A1 CA2195779 A1 CA 2195779A1
Authority
CA
Canada
Prior art keywords
agonist
hexane
acts
substance
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002195779A
Other languages
English (en)
Inventor
David Reed Helton
Mary Jeanne Kallman
James Allen Monn
Darryle Darwin Schoepp
Joseph Patrick Tizzano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/496,642 external-priority patent/US5661184A/en
Application filed by Individual filed Critical Individual
Publication of CA2195779A1 publication Critical patent/CA2195779A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/38—Unsaturated compounds containing keto groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Utilisation d'un agoniste qui agit au niveau des récepteurs dits métabotropiques du glutamate à liaison AMP cyclique à couplage négatif, pour l'obtention d'un médicament destiné au traitement des troubles de dépendance dus aux substances toxiques.
CA002195779A 1994-08-12 1995-08-14 Composition et methode de protection contre la toxicomanie Abandoned CA2195779A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US28995794A 1994-08-12 1994-08-12
US08/289,957 1994-08-12
US33734994A 1994-11-10 1994-11-10
US08/337,349 1994-11-10
US08/496,642 1995-06-29
US08/496,642 US5661184A (en) 1994-08-12 1995-06-29 Psychiatric agents

Publications (1)

Publication Number Publication Date
CA2195779A1 true CA2195779A1 (fr) 1996-02-22

Family

ID=27403948

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002195779A Abandoned CA2195779A1 (fr) 1994-08-12 1995-08-14 Composition et methode de protection contre la toxicomanie

Country Status (5)

Country Link
EP (1) EP0776200A4 (fr)
JP (1) JP3618104B2 (fr)
AU (1) AU3325095A (fr)
CA (1) CA2195779A1 (fr)
WO (1) WO1996004900A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9611511A (pt) * 1995-11-16 1999-05-04 Lilly Co Eli Derivados de aminoácidos excitatórios
GB9605429D0 (en) * 1995-11-16 1996-05-15 Lilly Co Eli Excitatory amino acid receptor antagonists
ZA969485B (en) * 1995-11-16 1998-05-12 Lilly Co Eli Excitatory amino acid receptor antagonists.
JP2000500752A (ja) * 1995-11-16 2000-01-25 イーライ・リリー・アンド・カンパニー 興奮性アミノ酸受容体アンタゴニスト
US5912248A (en) * 1995-11-16 1999-06-15 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5688826A (en) * 1995-11-16 1997-11-18 Eli Lilly And Company Excitatory amino acid derivatives
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
JP4192331B2 (ja) 1999-04-16 2008-12-10 住友化学株式会社 光学活性２−オキソビシクロ［３．１．０］ヘキサン−６−カルボン酸誘導体の製造方法
AU2018310881C1 (en) 2017-07-31 2021-12-16 Novartis Ag Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use

Also Published As

Publication number Publication date
EP0776200A1 (fr) 1997-06-04
JP3618104B2 (ja) 2005-02-09
JPH10504038A (ja) 1998-04-14
WO1996004900A1 (fr) 1996-02-22
EP0776200A4 (fr) 2001-01-17
AU3325095A (en) 1996-03-07

Similar Documents

Publication Publication Date Title
US5661184A (en) Psychiatric agents
AP758A (en) Synthetic excitatory amino acids.
EP0776201B1 (fr) Traitement de l'anxiété
US5519019A (en) N-acyl-2,3-benzoidazepine derivatives, pharmaceutical compositions containing them and process for preparing same
EA003946B1 (ru) Бицикло[2.2.1]гептаны и родственные соединения
CA2195779A1 (fr) Composition et methode de protection contre la toxicomanie
JPH11509846A (ja) ヘテロ環式化合物、それらの調製及び使用
CA2285192A1 (fr) Agents a action pharmacologique
US5639751A (en) N-acyl-2,3-benzodiazepine derivatives for treating acute and chronic neurodegenerative disorders
US5521174A (en) N-acyl-2,3-benzodiazepine derivatives and a method of treating spasms of the skeletal musculature therewith
EP1512679B1 (fr) Nouveaux dérivés d'adamantane à activités neuroprotectrices, antidépressives et antiischémiques, et leur procédé de préparation
WO2001002342A1 (fr) Analogues de 2-aminoindane
EP1194399A2 (fr) Nouveaux amino-indanes
HK1013958B (en) Treating anxiety
EP0928792B1 (fr) Hexanes (3.1.0) bicycliques et composés apparentés
HK1013983B (en) Synthetic excitatory amino acids
IL133493A (en) 2-spiro-5'-hydantoinbicyclo [3.1.0] hexane-6-carboxylic acid derivatives
CA2407777A1 (fr) Nouveaux composes spiro¬2.4|heptane amino carboxy et derives associes
MXPA99000392A (en) Bicycle [3.1.0] hexants and related compounds

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead